Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Rhea-AI Summary

Kalaris (NASDAQ: KLRS) will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego.

The Feb 26 presentation by Dean Eliott, MD will cover safety, tolerability, pharmacokinetics and early efficacy after intravitreal dosing in treatment‑naive neovascular AMD.

News Market Reaction – KLRS

-2.65%

7 alerts

-2.65% News Effect

-3.9% Trough in 53 min

-$5M Valuation Impact

$171M Market Cap

0.6x Rel. Volume

On the day this news was published, KLRS declined 2.65%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $171M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase: Phase 1 Conference edition: 49th Annual Meeting Meeting dates: February 25–28, 2026 +2 more

5 metrics

Phase Phase 1 TH103 first-in-human clinical study

Conference edition 49th Annual Meeting Macula Society meeting where TH103 data will be presented

Meeting dates February 25–28, 2026 Macula Society Annual Meeting schedule in San Diego

Presentation date February 26, 2026 Scheduled TH103 Phase 1 data presentation

Presentation time 8:15 am PT Session time for TH103 presentation

Market Reality Check

Price: $6.50 Vol: Volume 63,641 vs 20-day a...

normal vol

$6.50 Last Close

Volume Volume 63,641 vs 20-day average 85,305 (relative volume 0.75x) suggests no unusual trading ahead of this update. normal

Technical Shares at $9.61, trading above the 200-day MA of $5.02 and 25.5% below the 52-week high of $12.90.

Peers on Argus

KLRS fell 2.44% while peers showed mixed moves: ABOS +21.43%, NTRB +3.33%, STRO ...

KLRS fell 2.44% while peers showed mixed moves: ABOS +21.43%, NTRB +3.33%, STRO +7.43%, and ANEB -8.07%, IMUX -9.58%. This pattern points to stock-specific trading rather than a coordinated sector move.

Historical Context

5 past events · Latest: Dec 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Private placement financing	Positive	+20.3%	Oversubscribed $50M private placement to fund TH103 and operations.
Dec 17	Clinical data update	Positive	+20.3%	Positive initial Phase 1a TH103 data in treatment‑naïve neovascular AMD.
Nov 24	Conference participation	Neutral	-8.0%	Management presentation at Noble Capital emerging growth conference.
Nov 12	Earnings and updates	Neutral	-2.2%	Q3 2025 financials and TH103 program updates with runway into 2027.
Nov 03	CFO appointment	Positive	-0.8%	Appointment of new CFO to support financing and clinical advancement.

Pattern Detected

Positive financing and TH103 data have coincided with strong gains, while corporate and conference updates often saw negative reactions.

Recent Company History

Over the last few months, Kalaris has advanced TH103 while strengthening its balance sheet and leadership. On Dec 17, 2025, an oversubscribed $50.0M private placement and positive Phase 1a data for TH103 in neovascular AMD each saw a +20.32% share reaction. Earlier, Kalaris reported Q3 2025 results on Nov 12 with funding into 2027, yet shares fell 2.17%. A Noble Capital conference appearance on Nov 24 and the CFO appointment on Nov 3 also drew negative price reactions, underscoring a pattern where investors respond more favorably to clear clinical or financing milestones than to routine corporate updates.

Market Pulse Summary

This announcement highlights the upcoming presentation of Phase 1 clinical data for TH103 in treatme...

Analysis

This announcement highlights the upcoming presentation of Phase 1 clinical data for TH103 in treatment‑naïve neovascular AMD at a selective Macula Society forum. It follows prior positive Phase 1a results and recent financing intended to advance TH103. Investors may focus on safety, pharmacokinetics, and early efficacy signals shared at the meeting, and how they frame the ongoing Phase 1b/2 program and the company’s strategy around its lead retinal candidate.

Key Terms

phase 1, vegf, pharmacokinetics, intravitreal, +2 more

6 terms

phase 1 medical

"clinical data from its Phase 1 study of TH103 will be presented"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

vegf medical

"engineered by VEGF scientific pioneer Dr. Napoleone Ferrara"

Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels, like a fertilizer prompts plants to sprout. It matters to investors because drugs that block or mimic VEGF can dramatically change outcomes for cancers and eye diseases, making them major drivers of clinical trial results, regulatory approvals, market value and future revenue potential for biopharma companies.

pharmacokinetics medical

"The presentation will include safety, tolerability, pharmacokinetics and early efficacy"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

intravitreal medical

"following intravitreal administration of TH103 in patients"

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

neovascular age-related macular degeneration medical

"treatment-naive neovascular age-related macular degeneration"

A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.

hspg medical

"TH103, a Dual-Targeting VEGF and HSPG Inhibitor"

Heparan sulfate proteoglycans (HSPGs) are large molecules found on cell surfaces and in connective tissue that act like molecular Velcro, helping cells stick together, communicate, and control the movement of signaling molecules. Investors track HSPGs because they play a role in disease processes and drug targeting—changes or therapies that affect HSPGs can alter how a treatment works, influence clinical trial outcomes, and affect the commercial prospects of biotech and pharmaceutical investments.

AI-generated analysis. Not financial advice.

BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California.

TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal administration of TH103 in patients with treatment-naive neovascular age-related macular degeneration. The data will be presented during a scientific session attended by leading retinal specialists and clinical investigators.

Presentation Details:

• Title: First-in-Human Evaluation of TH103, a Dual-Targeting VEGF and HSPG Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD
• Speaker: Dean Eliott, MD, S.E. Gragoudas Professor of Ophthalmology, Harvard Medical School, Director Emeritus of Retina Service, Massachusetts Eye & Ear Infirmary
• Date: Thursday, February 26, 2026
• Time: 8:15 am PT
• Session: Neovascular AMD I: Clinical Trials
• Location: Southpointe Ballroom, Hotel Del Coronado, San Diego, CA
  
  

The Macula Society Annual Meeting is a highly selective, invitation-only forum where internationally recognized retinal experts convene to present and critically evaluate emerging clinical data and novel therapeutic strategies in retinal vascular and macular disease.

About Kalaris

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.

For more information, visit www.kalaristx.com.

Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com

FAQ

When will Kalaris (KLRS) present TH103 Phase 1 data at the Macula Society meeting?

Kalaris will present on February 26, 2026 at 8:15 am PT. According to Kalaris, the presentation is part of the Neovascular AMD I: Clinical Trials session at the Hotel Del Coronado in San Diego.

What Phase 1 TH103 results will Kalaris (KLRS) report at the Feb 26, 2026 presentation?

Kalaris will report safety, tolerability, pharmacokinetics and early efficacy outcomes from the Phase 1 study. According to Kalaris, the data reflect intravitreal administration in treatment‑naive neovascular age‑related macular degeneration patients.

Who is presenting Kalaris (KLRS) TH103 data at the Macula Society Annual Meeting?

Dean Eliott, MD will present the TH103 Phase 1 findings on behalf of Kalaris. According to Kalaris, he is S.E. Gragoudas Professor of Ophthalmology and Director Emeritus of Retina Service, Massachusetts Eye & Ear.

What is TH103 and how is Kalaris (KLRS) describing its mechanism at the 2026 Macula Society talk?

TH103 is described as a dual‑targeting VEGF and HSPG inhibitor engineered for enhanced VEGF inhibition and increased intraocular retention. According to Kalaris, it was engineered by VEGF pioneer Dr. Napoleone Ferrara.

Where and in which session will Kalaris (KLRS) present TH103 Phase 1 data at the Feb 2026 meeting?

The presentation is in the Neovascular AMD I: Clinical Trials session on Feb 26, 2026 at the Southpointe Ballroom, Hotel Del Coronado. According to Kalaris, the session gathers leading retinal specialists and investigators.